Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Neumeister

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Blood|February 21, 2014
NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomasAlexander J A Deutsch, Beate Rinner, Kerstin Wenzl, et al.
Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Journal of Biotechnology|February 5, 2020
Evaluation of host-based molecular markers for the early detection of human sepsisElisabeth Ullrich, Petra Heidinger, Jung Soh, et al.
Critical Care (London, England)|May 1, 2015
Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patientsSusanne Eigl, Juergen Prattes, Michaela Lackner, et al.
Wiener Klinische Wochenschrift|June 3, 2024
Correction to: Treatment of haemophilia in AustriaChristoph Male, Cihan Ay, Richard Crevenna, et al.
Wiener Klinische Wochenschrift|August 28, 2024
Correction to: Treatment of haemophilia in AustriaChristoph Male, Cihan Ay, Richard Crevenna, et al.
Wiener Klinische Wochenschrift|May 14, 2024
[Treatment of haemophilia in Austria]Christoph Male, Cihan Ay, Richard Crevenna, et al.
Blood Cancer Journal|September 8, 2018
Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcomeJulia J Unterluggauer, Katharina Prochazka, Peter V Tomazic, et al.
Journal of Personalized Medicine|July 2, 2021
Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic SclerosisPaul Gressenberger, Philipp Jud, Gabor Kovacs, et al.
Cancer Research|March 3, 2017
NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic GenesAlexander J A Deutsch, Beate Rinner, Martin Pichler, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Blood|February 21, 2014
NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomasAlexander J A Deutsch, Beate Rinner, Kerstin Wenzl, et al.
Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.
Journal of Biotechnology|February 5, 2020
Evaluation of host-based molecular markers for the early detection of human sepsisElisabeth Ullrich, Petra Heidinger, Jung Soh, et al.
Critical Care (London, England)|May 1, 2015
Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patientsSusanne Eigl, Juergen Prattes, Michaela Lackner, et al.
Wiener Klinische Wochenschrift|June 3, 2024
Correction to: Treatment of haemophilia in AustriaChristoph Male, Cihan Ay, Richard Crevenna, et al.
Wiener Klinische Wochenschrift|August 28, 2024
Correction to: Treatment of haemophilia in AustriaChristoph Male, Cihan Ay, Richard Crevenna, et al.
Wiener Klinische Wochenschrift|May 14, 2024
[Treatment of haemophilia in Austria]Christoph Male, Cihan Ay, Richard Crevenna, et al.
Blood Cancer Journal|September 8, 2018
Expression profile of translation initiation factor eIF2B5 in diffuse large B-cell lymphoma and its correlation to clinical outcomeJulia J Unterluggauer, Katharina Prochazka, Peter V Tomazic, et al.
Journal of Personalized Medicine|July 2, 2021
Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic SclerosisPaul Gressenberger, Philipp Jud, Gabor Kovacs, et al.
Cancer Research|March 3, 2017
NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic GenesAlexander J A Deutsch, Beate Rinner, Martin Pichler, et al.
Pageof 9